A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

NCT05342636 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Coformulation favezelimab/pembrolizumab
BIOLOGICAL: MK-4830
DRUG: Lenvatinib
DRUG: Irinotecan
DRUG: Paclitaxel

Sponsor

Merck Sharp & Dohme LLC